Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,961 to 2,980 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 133 of 1,219 118 of 1,241 | 1.4 points -1.0 to 3.8 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 157 of 1,219 113 of 1,241 | 3.8 points 1.3 to 6.3 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 241 of 1,219 198 of 1,241 | 3.8 points 0.8 to 6.8 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 183 of 1,219 152 of 1,241 | 2.8 points 0.1 to 5.5 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 87 of 1,219 50 of 1,241 | 3.1 points 1.3 to 5.0 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 67 of 1,219 49 of 1,241 | 1.5 points -0.1 to 3.3 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 112 of 1,219 86 of 1,241 | 2.3 points 0.1 to 4.4 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 211 of 1,219 171 of 1,241 | 3.5 points 0.7 to 6.4 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 90 of 1,219 50 of 1,241 | 3.4 points 1.5 to 5.2 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 65 of 1,219 48 of 1,241 | 1.5 points -0.2 to 3.2 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 150 of 1,219 132 of 1,241 | 1.7 points -0.9 to 4.2 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 39 of 1,219 32 of 1,241 | 0.6 points -0.7 to 2.0 | 2,460 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Exposed Cohort vs Unexposed Cohort: Number of Subjects With Pre-specified Neonate-related Outcomes, Resulting in Neonates Small for Their Gestational Age | 69 of 1,199 62 of 1,259 | 0.8 points -1.0 to 2.6 | 2,458 | NCT02757950 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. |
| Exposed Cohort vs Unexposed Cohort: Number of Subjects Reporting Gestational Diabetes | 10 of 1,199 22 of 1,259 | -0.9 points -1.9 to -0.0 | 2,458 | NCT02757950 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. |
| Exposed Cohort vs Unexposed Cohort: Number of Subjects With Pre-specified Neonate-related Outcomes Resulting in Preterm Birth | 64 of 1,199 121 of 1,259 | -4.3 points -6.4 to -2.2 | 2,458 | NCT02757950 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. |
| Exposed Cohort vs Unexposed Cohort: Number of Subjects Reporting Pregnancy Hemorrhage | 4 of 1,199 19 of 1,259 | -1.2 points -2.0 to -0.4 | 2,458 | NCT02757950 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. |
| Exposed Cohort vs Unexposed Cohort: Number of Subjects Reporting Cases of Congenital Anomalies in the Neonates | 3 of 1,199 22 of 1,259 | -1.5 points -2.4 to -0.7 | 2,458 | NCT02757950 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil. |
| Group 1 vs Group 2: Impact of Remote Patient Navigation Services | 529 of 1,330 284 of 1,127 | 14.6 points 10.9 to 18.2 | 2,457 | NCT04514341 Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up |
| TDF/FTC vs Placebo: Grade 2, 3, or 4 Clinical Adverse Events | 157 of 1,226 162 of 1,230 | -0.4 points -3.0 to 2.3 | 2,456 | NCT00458393 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men |
| TDF/FTC vs Placebo: serious adverse events | 92 of 1,226 94 of 1,230 | -0.1 points -2.2 to 2.0 | 2,456 | NCT00458393 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men |
Code
curl "https://conductscience.org/api/comparisons/v1?page=149"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=149
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-13c67d1e",
"title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI",
"summary": "133 of 1219 against 118 of 1241; risk difference 1.4 points, 95% interval -1.0 to 3.8; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-13c67d1e",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2460,
"risk_difference": {
"value": 0.014021215260127215,
"lower": -0.009954433206044246,
"upper": 0.03808762275203276
},
"group_1": "133 of 1,219",
"group_2": "118 of 1,241",
"difference": "1.4 points",
"interval": "-1.0 to 3.8",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-1d464c00",
"title": "Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization",
"summary": "157 of 1219 against 113 of 1241; risk difference 3.8 points, 95% interval 1.3 to 6.3; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-1d464c00",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2460,
"risk_difference": {
"value": 0.03773849319695738,
"lower": 0.013032528033280918,
"upper": 0.0625820918554061
},
"group_1": "157 of 1,219",
"group_2": "113 of 1,241",
"difference": "3.8 points",
"interval": "1.3 to 6.3",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=150",
"request_id": "HsMULMIzEC6ISshV"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant